Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Interest Expenses data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Interest Expenses rose 36366.67% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $4.9 million, up 187.34%, while the annual FY2025 figure was $4.9 million, 125.22% up from the prior year.
  • Interest Expenses reached $3.3 million in Q4 2025 per VRDN's latest filing, up from $566000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.3 million in Q4 2025 and bottomed at $3000.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $530625.0, with a median of $457000.0 recorded in 2023.
  • Peak YoY movement for Interest Expenses: tumbled 98.33% in 2021, then surged 36366.67% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $3000.0 in 2021, then skyrocketed by 5500.0% to $168000.0 in 2022, then soared by 138.1% to $400000.0 in 2023, then tumbled by 97.75% to $9000.0 in 2024, then soared by 36366.67% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $3.3 million in Q4 2025, $566000.0 in Q3 2025, and $514000.0 in Q2 2025.